Overview

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

Status:
Completed

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Gemphire Therapeutics, Inc.
NeuroBo Pharmaceuticals Inc.

Treatments:

Cobalt